ArticleOcular oncology and pathology2020
BAP1 Immunoreactivity Correlates with Gene Expression Class in Uveal Melanoma.
Article in Ocular oncology and pathology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 37 citations in OpenAlex.
- CDK6/4 inactivates BAP1 deubiquitinase destabilizing VHL to promote metastatic colonization in liver.Molecular cancer · 2026Article
- Article
- The latestExpert opinion on drug discovery · 2026Review
- Metastatic potential of small posterior uveal melanomas.Acta ophthalmologica · 2026Article
- Prognostic value of BAP1 expression in uveal melanoma: a comparative study with histopathological factors in a large Spanish cohort.Frontiers in oncology · 2026Article
- Ocular Melanoma: A Comprehensive Review with a Focus on Molecular Biology.International journal of molecular sciences · 2025Review
- Introducing the Event-Adjusted Rank Sum (EARS) Test: A Simple Approach to Survival Analysis Independent of Proportional Hazards.BioMed research international · 2025Article
- Impact of Driver Mutations on Metastasis-Free Survival in Uveal Melanoma: A Meta-Analysis.Cancers · 2024Review
- The prognostic implication of visual acuity at the time of uveal melanoma diagnosis.Eye (London, England) · 2023Article
- Multiorgan Involvement of Dormant Uveal Melanoma Micrometastases in Postmortem Tissue From Patients Without Coexisting Macrometastases.American journal of clinical pathology · 2023Article
- Digital morphometry and cluster analysis identifies four types of melanocyte during uveal melanoma progression.Communications medicine · 2023Article
- A serum protein signature at the time of Uveal Melanoma diagnosis predicts long-term patient survival.BMC cancer · 2023Article
- Adjuvant melatonin for uveal melanoma (AMUM): protocol for a randomized open-label phase III study.Trials · 2023Article
- The evidence forTranslational cancer research · 2023Review
- The prognostic implication of latitude in uveal melanoma: a nationwide observational cohort study of all patients born in Sweden between 1947 and 1989.Discover oncology · 2022Article
- Correlation between BAP1 Localization, Driver Mutations, and Patient Survival in Uveal Melanoma.Cancers · 2022Article
- Vasculogenic mimicry correlates to presenting symptoms and mortality in uveal melanoma.Journal of cancer research and clinical oncology · 2022Article
- BAP1 Immunostain Status in Intraocular Biopsy Specimens for Uveal Melanoma Highly Correlates with Other Prognostic Markers.Ocular oncology and pathology · 2022Article
- Long-term relative survival in uveal melanoma: a systematic review and meta-analysis.Communications medicine · 2022Article
- Prognostic Biomarkers in Uveal Melanoma: The Status Quo, Recent Advances and Future Directions.Cancers · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 2 countries.
Funding
Abstract
backgroundUveal melanoma (UM) is the most common intraocular tumour in adults. Currently there are different tests available to determine the risk of UM for metastasis, among which include BRCA1-associated protein-1 (BAP1) immunohistochemistry (IHC) and gene expression profiling (GEP). BAP1 is a deubiquitylating enzyme (DUB) that has tumour suppressor activity, the loss of which therefore is associated with higher risk for tumour growth and metastasis.
objectivesTo compare and correlate the prognostic significance of BAP1-IHC staining patterns and GEP in the prediction of UM's risk for metastasis.
methodsThis is a retrospective chart review with prospective follow-up of patients with primary UM who underwent enucleation from the year 2008 to 2018. Clinical history, histopathologic findings, GEP classification, BAP1-IHC of the formalin-fixed paraffin-embedded tissues, and follow-up data for metastasis were collected and statistically analysed.
resultsA total of 30 enucleated eyes with UM were included in the study. All class 1a tumours had high nuclear BAP1 expression and all class 2 had low nuclear BAP1 expression. Fifty percent of the class 1b tumours had low nuclear BAP1 expression. Among the tumours with low nuclear BAP1 expression, 68% developed metastasis, while 9% developed metastasis among high nuclear expression. Fifty-five percent developed metastasis in tumours with high cytoplasmic expression and 42% for low cytoplasmic expression. Predictive values for metastasis (positive predictive value, negative predictive value) are as follows: (1) nuclear BAP1-IHC (68%, 91%), (2) cytoplasmic BAP1-IHC (55%, 58%), and (3) GEP (73%, 80%). Nuclear BAP1-IHC and GEP had the same accuracy rate of 77% and cytoplasmic BAP1-IHC had an accuracy of 57%.
conclusionLow nuclear BAP1-IHC strongly correlates with GEP class 2 and was equally accurate in the prediction of metastasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.